

# Genetic and clinical features of patients with cystic fibrosis diagnosed after the age of 16 years

King-Han Gan, Willem P Geus, Willem Bakker, Cornelis B H W Lamers, Harry G M Heijerman

## Abstract

**Background** - Cystic fibrosis is usually diagnosed in childhood, but a number of patients are not diagnosed until adulthood. The aim of this study was to investigate whether patients diagnosed at an older age had a different genetic constitution, manifestations of disease, and prognosis from those diagnosed at an early age.

**Methods** - Clinical data and results of lung function tests and DNA analysis of 143 adult patients with cystic fibrosis were entered into a computerised database. Patients diagnosed before their 16th birthday (early diagnosis, ED) were compared with those diagnosed at 16 years of age or older (late diagnosis, LD).

**Results** - Mean age of diagnosis of the ED group was 4.6 years compared with 27.7 years for the LD group. Mean (SD) percentage predicted pulmonary function was better for the LD group than for the ED group: forced expiratory volume in one second (FEV<sub>1</sub>) 72.5 (31.1)% and 52.0 (24.8)%, and forced vital capacity (FVC) 89.8 (25.7)% and 71.9 (23.0)%, respectively. Colonisation with *Pseudomonas aeruginosa* was present in 70% of the ED group and 24% of the LD group. In the ED group 81% had pancreatic insufficiency compared with only 12% of the LD group. None of the LD group was homozygous for  $\Delta F508$  compared with 58% of the ED group. In the LD group 72% were compound  $\Delta F508$  heterozygotes and 28% had two non- $\Delta F508$  mutations.

**Conclusions** - Among this group of 143 adult patients with cystic fibrosis late diagnosis is caused mainly by delayed expression and mild progression of clinical symptoms. Late diagnosis is associated with milder pulmonary disease, less pancreatic insufficiency, and different cystic fibrosis mutations. Since mortality in cystic fibrosis depends on the progression of pulmonary disease, patients with a late diagnosis have a better prognosis than those diagnosed early.

(Thorax 1995;50:1301-1304)

Keywords: cystic fibrosis, late diagnosis, prognosis.

Cystic fibrosis is the most common serious genetic disorder among Caucasian populations with an incidence of about one in 2500 live

births and with one in 25 persons as asymptomatic carriers.<sup>1</sup> The disease is caused by mutations in the gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR), a c-AMP dependent chloride channel.<sup>2-4</sup>

Most patients with cystic fibrosis in northern Europe have a mutation that causes the deletion of amino acid 508 (phenylalanine) of the CFTR protein, the so-called  $\Delta F508$  mutation.<sup>5</sup> In The Netherlands the frequency of this mutation on chromosomes of patients with cystic fibrosis is 77.1%.<sup>6</sup> More than 400 other mutations of the CFTR gene have now been found and most of them are rare.<sup>6,7</sup>

Cystic fibrosis is usually diagnosed in childhood, with up to 50% of patients presenting in the first year of life.<sup>8</sup> Typical modes of presentation are meconium ileus, failure to thrive, recurrent pulmonary infections, diarrhoea, and steatorrhea. It may, however, be diagnosed in adult patients.<sup>8-11</sup> Patients diagnosed late usually present with respiratory symptoms, or with male infertility due to congenital bilateral absence of the vas deferens (CBAVD).<sup>12</sup>

Diagnosis is confirmed by pilocarpine sweat iontophoresis, with chloride levels in sweat exceeding 70 mmol/l. Diagnosis can also be made with electrophysiological tests of nasal<sup>13</sup> or rectal epithelium.<sup>14</sup>

In our centre for adult patients with cystic fibrosis we define late diagnosis (LD) as diagnosis at the age of 16 or older. Patients diagnosed before their 16th birthday are considered to have an early diagnosis (ED). Almost 20% of our patients with cystic fibrosis were diagnosed after their 16th birthday. In this study we compared the characteristics of this group of LD patients with the characteristics of ED patients.

## Methods

One hundred and forty three adult patients with cystic fibrosis who attended our clinic and for whom complete data (including DNA analysis) was available on 1 January 1995 were studied. Diagnosis was made by characteristic symptoms of cystic fibrosis, together with a chloride concentration in sweat of >70 mmol/l. Sweat tests were usually performed at the referring hospital by various methods (classic pilocarpine test, chloride electrode, etc), and are not directly comparable. In a small number of patients the sweat test results were equivocal so electrophysiological tests of rectal epithelium

Adult Cystic Fibrosis  
Centre, Department of  
Pulmonology  
K-H Gan  
W Bakker  
H G M Heijerman

Department of  
Intensive Care  
W P Geus

Leyenburg Hospital,  
2545 CH The Hague,  
The Netherlands

Department of  
Gastroenterology,  
University Hospital,  
Leiden,  
The Netherlands  
C B H W Lamers  
W P Geus

Reprint requests to:  
Dr H G M Heijerman.

Received 17 February 1995  
Returned to authors  
28 April 1995  
Revised version received  
27 June 1995  
Accepted for publication  
22 August 1995

were performed to confirm the diagnosis of cystic fibrosis.<sup>14</sup>

One hundred and thirty eight patients were Dutch, two were of Italian–Dutch descent, two were of Indonesian descent and one was of Chinese descent. There were 13 sets of siblings in our sample: a family of four, a family of three, and 11 sibling pairs, among them one pair of twins.

Demographic data including age, sex, age at diagnosis, presenting signs, and smoking history were taken from patients' charts. Age at diagnosis was determined as the age on the day of a first positive sweat test. For height and weight the values measured at the last clinic visit were used. Body mass index was calculated as weight/height<sup>2</sup> (weight in kilograms, height in metres). The presenting signs were those that caused the patient to seek medical attention and were categorised as follows: gastrointestinal complaints including diarrhoea, steatorrhoea, vomiting and abdominal pain; meconium ileus and rectal prolapse; ear, nose and throat complaints including nasal polyps and recurrent or chronic sinusitis.

Lung function tests were regularly performed in all patients and the best values for forced expiratory volume in one second (FEV<sub>1</sub>) and forced vital capacity (FVC) over the previous year was used. The values were compared with reference values of the European Respiratory Society.<sup>15</sup> An age-independent yearly decline in FEV<sub>1</sub> was calculated by dividing the difference between predicted FEV<sub>1</sub> and actual FEV<sub>1</sub> (expressed as a percentage of reference values) by age.

Patients with consecutive sputum cultures growing *Pseudomonas aeruginosa* for at least six months were considered to be colonised with this microorganism.

Pancreatic insufficiency was considered to be present when patients had a faecal fat excretion of >10% fat intake during three day fat balance studies, or when gross steatorrhoea necessitated the use of pancreatic enzyme supplements, and diabetes mellitus (DM) was considered to be present when insulin was needed to control a patient's blood glucose concentration.

DNA was analysed for the following mutations: E60X, R117H, A455E, ΔI507, ΔF508, G542X, S549N, G550X, G551D, R553X, R560T, R1162X, S1251N, W1282X, N1303K, 621 + 1G→T, 1717-1G→A. These mutations represent 80% of the expected cystic fibrosis mutations in The Netherlands. DNA testing was done at the University of Groningen, Department of Medical Genetics and at

University Hospital Rotterdam, Department of Clinical Genetics.

All data were entered into a computerised database. Continuous variables were compared by a two tailed unpaired *t* test. Categorical variables were compared using the  $\chi^2$  test. A *p* value of <0.05 was considered significant.

## Results

Table 1 summarises the demographic data of the patient population. There were 118 patients with ED and 25 with LD. The mean age of the ED and LD patients was 26.8 and 35.7 years, respectively. The mean age of diagnosis in the ED group was 4.6 years (31 patients were diagnosed in the first year of life), and 27.7 years in the LD group. The mean height was below average for both men and women in the ED group: average height for men was around the 15th percentile and for women the 30th percentile for height compared with the normal Dutch population.<sup>16</sup> In the LD group both men and women were around the 50th percentile for height. Body mass index (BMI) was a little higher in the LD group (*p*=0.05), although for both groups it fell in the normal range (20.2 (2.4) in the ED group and 21.4 (2.8) in the LD group).

In the ED group 47% presented with recurrent respiratory tract infections, 45% with abnormal stools and other gastrointestinal tract symptoms, 5% with meconium ileus, 2.5% with rectal prolapse, 14% with poor growth or weight gain, and 6% with ENT symptoms such as nasal polyps or recurrent sinusitis. In 14% diagnosis was made because of a sibling or family member with cystic fibrosis (because many patients had more than one presenting symptom, the total exceeds 100%). In the LD group the presenting signs were recurrent respiratory tract infections in 92%, gastrointestinal tract complaints in 8%, one patient (4%) presented with male infertility, and one patient (4%) with oesophageal varices. In 24% the diagnosis was made because of cystic fibrosis in a sibling.

DNA of all patients was analysed for CFTR mutations. In the ED group the ΔF508 mutation was found on 74.2% of all cystic fibrosis chromosomes tested. Sixty eight patients (47%) were homozygous for the ΔF508 mutation (table 2). In the LD group the frequency of the ΔF508 mutation was 36.0%, and none of the patients was homozygous for this mutation (table 2). The difference between the two groups is highly significant (*p*<0.0001).

Table 1 Basic characteristics of early and late diagnosis groups

	Early diagnosis ( <i>n</i> =118)	Late diagnosis ( <i>n</i> =25)	<i>p</i>
Men/women (abs. number (%))	62/56 (53/47)	12/13 (48/52)	NS
Mean age (range) (years)	26.8 (15.8–42.7)	35.7 (21.4–55.6)	<0.005
Mean age at diagnosis (range) (years)	4.6 (0.0–15.9)	27.7 (16.9–43.4)	<0.005
Mean height (height percentile) men	1.75 (12.9)	1.83 (53.9)	<0.05
Mean height (height percentile) women	1.66 (33.0)	1.68 (44.0)	NS
BMI	20.2 (2.4)	21.4 (2.8)	<0.05

BMI=body mass index.

Table 2 Presence of  $\Delta F508$  mutation in 136 patients

	All patients	Early diagnosis	Late diagnosis
$\Delta F508$ 2X	68 (47%)	68 (58%)	0 (0%)
$\Delta F508$ 1X	57 (40%)	39 (33%)	18 (72%)
Two other mutations	18 (13%)	11 (9%)	7 (28%)
$\Delta F508$ frequency	67.3%	74.2%	36.0%


Cumulative percentages of patients with cystic fibrosis diagnosed by age and by the presence of  $\Delta F508$  mutation.

Table 3 CFTR mutations in 278 chromosomes of adult cystic fibrosis patients

	Early diagnosis (n=118)		Late diagnosis (n=25)	
	n	%	n	%
$\Delta F508^s$	175	74.2	18	36.0
A455E <sup>m</sup>	12	5.1	14	28.0
1717-1 <sup>s</sup>	6	2.5	1	2.0
G542X <sup>s</sup>	4	1.7	—	—
W1282X <sup>s</sup>	3	1.3	—	—
R553X <sup>s</sup>	1	0.4	1	2.0
S1251N	2	0.8	—	—
N1303K <sup>s</sup>	1	0.4	—	—
E60X	1	0.4	3	6.0
Not identified	31	13.2	13	26.0
Total	236		50	

Mutations not found: R117H,  $\Delta I507$ , S549N, G550X, G551D, R560T, R1162X, 621 + 1G → T.

Mutations marked 's' are considered severe, those marked 'm' are considered mild.<sup>29</sup>

The influence of the presence of the  $\Delta F508$  mutation on the age of diagnosis is shown in the figure. All  $\Delta F508$  homozygotes were diagnosed by age 13, whereas 39% of patients not bearing the  $\Delta F508$  mutation were diagnosed at an age older than 16 years. The frequency of all CFTR mutations found is listed in table 3. The A455E mutation was relatively frequent in the LD group. In the ED group

Table 4 Mean (SD) pulmonary parameters expressed as a percentage of predicted values

	Early diagnosis (n=118)	Late diagnosis (n=25)	p
FEV <sub>1</sub>	52.0 (24.8)	72.5 (31.1)	<0.005
FVC	71.9 (23.0)	89.8 (25.7)	<0.005
Yearly decline in FEV <sub>1</sub>	1.82 (0.97)	0.74 (0.88)	<0.005
No. (%) colonised with <i>P. aeruginosa</i>	83 (70.3%)	6 (24%)	<0.005

FEV<sub>1</sub> = forced expiratory volume in one second; FVC = forced vital capacity.

Table 5 Number of patients (%) with non-pulmonary disease symptoms

	Early diagnosis (n=118)	Late diagnosis (n=25)	p
Pancreatic insufficiency	96 (81%)	3 (12%)	<0.005
Diabetes mellitus	17 (14%)	2 (8%)	NS

13.2% of mutations could not be identified compared with 26.0% in the LD group.

Table 4 lists the results of lung function tests for the two groups. In the ED group FEV<sub>1</sub> and FVC were significantly lower than in the LD group, despite the average higher age of the latter group. In both groups of patients the decline in FEV<sub>1</sub> was faster than in the general population. However, the average annual decline in FEV<sub>1</sub> was more than twice as large in ED patients than in LD patients. In the ED group a decline of FEV<sub>1</sub> to 30% is predicted by 38.3 years and for the LD group at 94.9 years. When the FEV<sub>1</sub> falls below 30% the likelihood of death within two years is increased and serious disability can be anticipated.<sup>17</sup>

In the ED group colonisation with *Pseudomonas aeruginosa* was present in 83 patients (70.3%) compared with six patients (24%) in the LD group (p<0.005).

There was one active smoker in the ED group, and one active and seven former smokers in the LD group.

Non-pulmonary disease symptoms are summarised in table 5. Pancreatic insufficiency was present in 96 patients (81%) of the ED group compared with only three (12%) in the LD group (p<0.005). Diabetes mellitus occurred in 17 patients (14%) in the ED group and in two (8%) of the LD group (NS). All ED patients with diabetes had an exocrine pancreatic insufficiency. In the LD group one of the patients with diabetes had an exocrine pancreatic insufficiency while in the other patient diabetes was associated with the use of oral corticosteroids.

## Discussion

This study describes the clinical and genetic features of patients in whom cystic fibrosis was diagnosed late compared with those in whom it was diagnosed early. Late diagnosis appears to be not just a case of doctor or patient delay, but to constitute a separate patient group with a distinct genetic constitution and often milder pulmonary and non-pulmonary disease symptoms.

In earlier descriptions of groups of adult patients with cystic fibrosis 3.5–21% were diagnosed at 16 years or older.<sup>8,18–22</sup> In these reports on adult patients late diagnosis was not associated with milder disease. In fact, it was found that patients diagnosed at an early age generally did better than those diagnosed at a later age<sup>23,24</sup> or there was no difference.<sup>19,22</sup> However, our study shows that late diagnosis does not necessarily have to be detrimental to prognosis.

There are a number of reasons for late diagnosis. Firstly, mild or absent symptoms may delay a patient seeking medical attention. Secondly, a physician may not recognise cystic fibrosis, especially when the presenting symptoms are atypical. Finally, there may be problems in the diagnosis of cystic fibrosis as, for example, when there are repeated normal or borderline sweat tests.<sup>25,26</sup>

Most of those diagnosed early presented with a combination of gastrointestinal and pul-

monary symptoms, while in the late diagnosis group most were diagnosed because of recurrent pulmonary infections or because cystic fibrosis was found in a sibling. Gastrointestinal symptoms rarely led to the diagnosis of cystic fibrosis in this group. Until now the cystic fibrosis genotype was not predictive for pulmonary function or for prognosis.<sup>27</sup> Our results make it much more likely that there is a link between CFTR mutations and the severity of pulmonary disease. Among our patients all  $\Delta F508$  homozygotes were in the early diagnosis group who had more severe pulmonary and non-pulmonary disease. Most of those diagnosed at 16 years or older were pancreatic sufficient, which is closely related to the type of CFTR mutation.<sup>28,29</sup> The A455E mutation was frequently found among this group of patients and preliminary studies indicate that this mutation, known to be related to pancreatic sufficiency,<sup>29</sup> may be associated with mild pulmonary disease.<sup>30</sup> It seems that other CFTR mutations (some of which are still unidentified) in patients diagnosed late are associated with pancreatic sufficiency and also with mild pulmonary disease. It is doubtful that pancreatic and pulmonary status are determined entirely by independent genetic factors.<sup>28</sup>

The authors thank Drs Scheffer and Van der Hout (Department of Medical Genetics, University of Groningen) and Drs Halley and Van den Ouweland (Department of Clinical Genetics, University Hospital Rotterdam) for performing the DNA analysis.

- 1 Lewis PA. The epidemiology of cystic fibrosis. In: Hodson ME, Geddes DM, ed. *Cystic fibrosis*. 1st edn. London: Chapman and Hall, 1995:1-13.
- 2 Rommens JM, Iannuzzi MC, Kerem BS, Drumm ML, Melmer G, Dean M, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. *Science* 1989;245:1059-65.
- 3 Riordan JR, Rommens JM, Kerem BS, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science* 1989;245:1066-73.
- 4 Kerem BS, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, et al. Identification of the cystic fibrosis gene: genetic analysis. *Science* 1989;245:1073-80.
- 5 Population analysis of the major mutation in cystic fibrosis. *Hum Genet* 1990;85:391-453.
- 6 Cystic Fibrosis Genetic Analysis Consortium. Population variation of common cystic fibrosis mutations. *Hum Mutat* 1994;4:167-77.
- 7 Tsui LC. Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium. *Hum Mutat* 1992;1:197-203.
- 8 Penketh AR, Wise A, Mearns MB, Hodson ME, Batten JC. Cystic fibrosis in adolescents and adults. *Thorax* 1987;42:526-32.
- 9 Van Biezen P, Overbeek SE, Hilvering C. Cystic fibrosis in a 70 year old woman. *Thorax* 1992;47:202-3.
- 10 Su CT, Beamblossom B. Typical cystic fibrosis in an elderly woman. *Am J Med* 1989;86:701-3.
- 11 Hunt B, Geddes DM. Newly diagnosed cystic fibrosis in middle and later life. *Thorax* 1985;40:23-6.
- 12 Anguiano A, Oates RD, Amos JA, Dean M, Gerrard B, Stewart C, et al. Congenital bilateral absence of the vas deferens. A primarily genital form of cystic fibrosis. *JAMA* 1992;267:1794-7.
- 13 Alton EW, Currie D, Logan-Sinclair R, Warner JO, Hodson ME, Geddes DM. Nasal potential difference: a clinical diagnostic test for CF. *Eur Respir J* 1990;3:922-6.
- 14 Veeze HJ, Sinaasappel M, Bijman J, Bouquet J, De Jonge HR. Ion transport abnormalities in rectal suction biopsies from children with cystic fibrosis. *Gastroenterology* 1991;101:398-403.
- 15 Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report of Working Party on Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J* 1993;16(Suppl):5-40.
- 16 Van Wieringen JC, Roede M, Wit JM. Groeidiagrammen voor patiëntenzorg [Growth charts for patient care]. *Tijdschr Kindergeneesk* 1985;53:147-52.
- 17 Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. *N Engl J Med* 1992;326:1187-91.
- 18 di Sant'Agnes PA, Davis PB. Cystic fibrosis in adults. 75 cases and a review of 232 cases in literature. *Am J Med* 1979;66:121-32.
- 19 Huang NN, Schidlow DV, Szatrowski TH, Palmer J, Laraya-Cuasay LR, Yeung W, et al. Clinical features, survival rate, and prognostic factors in young adults with cystic fibrosis. *Am J Med* 1987;82:871-9.
- 20 Shwachman H, Kowalski M, Khaw KT. Cystic fibrosis: a new outlook. 70 patients above 25 years of age. *Medicine* 1977;56:129-49.
- 21 Stern RC, Boat TF, Doershuk CF, Tucker AS, Miller RB, Matthews LW. Cystic fibrosis diagnosed after age 13. *Ann Intern Med* 1977;87:188-91.
- 22 Burke W, Aitken ML, Chen SH, Scott CR. Variable severity of pulmonary disease in adults with identical cystic fibrosis mutations. *Chest* 1992;102:506-9.
- 23 Orenstein DM, Boat TF, Stern RC, Tucker AS, Charnock EL, Matthews LW, et al. The effect of early diagnosis and treatment in cystic fibrosis. *Am J Dis Child* 1977;131:973-5.
- 24 Dankert-Roelse JE, Te Meerman GJ, Martijn A, Ten Kate LP, Knol K. Survival and clinical outcome in patients with cystic fibrosis, with or without neonatal screening. *J Pediatr* 1989;114:362-7.
- 25 Augarten A, Kerem BS, Yahav Y, Noiman S, Rivlin Y, Tal A, et al. Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C → T mutation. *Lancet* 1993;342:25-6.
- 26 Veeze HJ, Van den Ouweland AMW, Timmers-Reeker AJM, Scheffer H, Bijman J, Sinaasappel M, et al. Increased incidence of  $\Delta F508/A455E$  patients by intestinal current measurements in case of borderline or even high normal sweat tests. (Abstract). *Pediatr Pulmonol* 1994;Suppl 10:220.
- 27 Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. *N Engl J Med* 1993;329:1308-13.
- 28 Santis G, Osborne L, Knight RA, Hodson ME. Independent genetic determinants of pancreatic and pulmonary status in cystic fibrosis. *Lancet* 1990;336:1081-4.
- 29 Kristidis P, Bozon D, Corey M, Markiewicz D, Rommens J, Tsui LC, et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. *Am J Hum Genet* 1992;50:1178-84.
- 30 Gan KH, Heyerman HGM, Bakker W. Correlation between genotype and phenotype in patients with cystic fibrosis (letter). *N Engl J Med* 1994;330:865-6.